In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI targets.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.